Z Squared Inc. current report, 07 April 2026

SEC Filing Summary: Coeptis Therapeutics Holdings, Inc. (COEP)

Business Context and Reporting Period

This Form 8-K was filed on April 7, 2026, by Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP). The filing reports a material event regarding the Company's proposed merger with Z Squared Inc.

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a corporate transaction event.

Material Changes

  • Nasdaq Listing Approval: Nasdaq has approved the listing of the post-merger Company's common stock on the Nasdaq Global Market.
  • New Ticker Symbol: The post-merger entity will trade under the ticker symbol "ZSQR".
  • Conditions: Approval is subject to customary conditions and the closing of the proposed merger with Z Squared Inc.

Guidance, Outlook, and Risks

The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the standard conditions of the merger closing. The primary contingency is the successful closing of the merger with Z Squared Inc.

Investor Verification Checklist

  • Verify the final closing date of the merger between Coeptis Therapeutics Holdings, Inc. and Z Squared Inc.
  • Confirm the exact date the ticker symbol changes from "COEP" to "ZSQR" on the Nasdaq Global Market.
  • Review the full press release (Exhibit 99.1) for details on the merger terms and exchange ratios.
  • Check for any subsequent filings regarding the satisfaction of customary closing conditions.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.